EUCTR2013-005009-30-GB进行中（未招募）1 期
An open label, randomised controlled feasibility pilot study to evaluate whether nasal fentanyl alone and in combination with buccal midazolam give better symptom control to dying patients when compared with standard as needed medication - Nasal Fentanyl and Buccal Midazolam for Dying Patients
Gloucestershire Hospitals NHS Foundation Trust and0 个研究点目标入组 20 人开始时间: 2019年2月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Pilot open label randomised controlled trial:
- •Adult hospice in-patients fitting the following criteria will be considered for inclusion. Where they have capacity they will be approached to see if they are willing to participate in the study.
- •If they lack capacity a carer / member of the family will be approached as a legal representative to see if they would consider giving consent on the patient’s behalf.
- •1. diagnosis of terminal cancer and thought to have an estimated prognosis of between 1 and 2 weeks
- •2. patients who, in the last 24 hours, have experienced at least one episode of breakthrough pain.
- •3. taking 60mg or more of oral morphine (or its equivalent) per 24 hours
- •4. have carers or family members who would be:
- •- willing to give the study medication to the patient
- •- likely to be at the hospice at least 25% of the time so that they are likely to be present to administer medication.
- •The contraceptive requirements are not applicable as the health status of patients is critical and predicted life span is short.
- •Qualitative Interview Study:
- •Family members / carers of a patient in the experimental arm of the open label randomised controlled trial, who has administered trial drug will be considered eligible to participate in the qualitative interviews.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •Pilot open label randomised controlled trial:
- •1. patients/ carers/ family members who will not agree to nasal or buccal drug application
- •2. patients / carers / family members who in the opinion of the clinical team would be too distressed by the idea of participation
- •3. patients with disease of the nasal/buccal mucosa preventing effective absorption of medication
- •4. families who are unable to administer breakthrough medication e.g. problems with dexterity
- •5. history of substance abuse – patient or carer / family.
- •6. patients with a previously known sensitivity to benzodiazepines and/or opioids
- •7. people who might not adequately understand verbal explanations or written information given in English. The feasibility study is only recruiting 20 patients and Gloucestershire has a only a very small percentage of people who are not English speaking. It has been decided that it is not cost effective to fund translation for this feasibility study although this information will have to be taken into account when planning a larger study. We will capture information on the numbers of patients that may have been excluded and the languages that might have been needed.
- •8. Participated in a palliative care trial within the last month.
- •Qualitative Interview Study:
- •Unable to understand sufficient English to take part in a semi-structured interview
研究者
相似试验
进行中（未招募）
不适用
Do food supplements containing live bacteria (probiotics) reduce or stop a particular infection (CPE) living in the bowel?ISRCTN11133689Manchester University NHS Foundation Trust40
已完成
不适用
Symptomatic treatment of patients suffering from productive cough associated with acute bronchitis.CTRI/2022/09/045509Dr Deepali Gaikwad60
招募中
3 期
Cardamom Extract Clinical trial on Covid patientsCTRI/2021/01/030601Zum Heilen Diagnostic Therapeutics ZH DT
尚未招募
3 期
Clinical trial on post covid patientsCTRI/2022/07/043655Zum Heilen Diagnostic and Therapeutics Pvt Ltd
已完成
4 期
Herbal product Clinical trial on COVID-19 patientsCTRI/2020/05/024967MiLab LifeSciences P Ltd42